The human immunodeficiency virus type 1 coreceptor activity of CCR5 depends on certain polar and charged residues in its amino-terminal domain. Since studies of chimeric receptors have indicated that the extracellular loops of CCR5 are also involved in viral fusion and entry, we have explored the role of bulky, polar and nonpolar residues in these regions. Selected amino acids in the three extracellular loops were individually changed to alanines, and the coreceptor activities of the mutant CCR5 proteins were tested in a luciferase reporter virus-based entry assay. We found that the cysteines in the extracellular loops of CCR5 are essential for coreceptor activity. However, only minor (two-to threefold) effects on coreceptor function were noted for all of the other alanine substitutions. We also demonstrated that when the first 19 residues of the amino-terminal region were separated from the rest of CCR5, by insertion of glycine/serine spacers between proline 19 and cysteine 20, coreceptor function decreased. Together with our previous studies, these data indicate that both an amino-terminal gp120-binding site and extracellular domain geometry play a role in viral entry.
gp120 interacts with residues in all four of these domains. Indeed, several studies that analyzed polymorphism of CCR5 genes from different species found that a number of amino acid changes in the extracellular loops (ECLs) impaired HIV-1 entry and/or cell-cell fusion (11, 18, 24) . However, systematic and exhaustive mutagenesis of residues in the CCR5 loops was not performed. We have now extended the alanine scanning approach to study the role of bulky, polar and nonpolar residues in the ECLs of CCR5. We sought to identify functionally relevant residues that the early chimera studies predicted might be found in these domains.
Using PCR-based site-directed mutagenesis, we individually changed the polar serine (S), cysteine (C), tyrosine (Y), threonine (T), asparagine (N), and glutamine (Q) residues and the nonpolar proline (P), phenylalanine (F), and tryptophan (W) residues to alanines (A), as described previously (13, 22) (Fig.  1) . A similar methodology was used to insert alternating glycine/serine (G/S) coding spacers between P19 and C20 in the Nt domain of CCR5. All CCR5 molecules used in this study had a 9-residue hemagglutinin (HA) tag as a carboxy-terminal extension, to allow detection by dot blotting with anti-HA antibodies (13, 22) . We tested the CCR5 mutants for their abilities to mediate the entry of different HIV-1 isolates into U87MG-CD4 cells. This is a human neuronal cell line that does not express CCR5, CCR3, or CXCR4 and is not infectable by any of our test isolates (6, 13, 22) . Briefly, cells were lipofected with wild-type or mutant CCR5 genes and then infected with a 200 to 500-ng/ml concentration of p24 from NLluc ϩ env Ϫ viruses complemented in trans by envelope glycoproteins from JR-FL (17) or Gun-1 (28) . Luciferase activities were measured in cell lysates 72 h postinfection as described previously (13, 22) .
Expression levels of mutant and wild-type CCR5 proteins were determined in each experiment (13, 22) . Thus, lipofected cells were lysed with detergent, and clarified lysates were diluted (1:1) in 1% sodium dodecyl sulfate-1 mM dithiothreitol. were scanned with the IS-1000 digital imaging system (Alpha Innotech Corporation). Integrated density values were used to standardize luciferase activities. In a separate set of experiments, we also analyzed CCR5 mutant protein expression by flow cytometry: cells were incubated with a panel of murine anti-CCR5 monoclonal antibodies (MAbs), washed, and then stained with phycoerythrin-conjugated goat anti-mouse immunoglobulin G (12). All mutants were thus shown to be present on the cell surface, and similar expression levels were measured by dot blotting and flow cytometry (data not shown). The same was true for the CCR5 molecules carrying insertions in the Nt domain (data not shown). Expression levels of all mutants were between 10 and 130% of wild-type-coreceptor expression ( Fig. 2 and 3) .
We found that only mutation of the three cysteine residues had a significant impact on viral entry (Fig. 2) . The coreceptor activity of mutants C101A and C178A was 1 to 5% of that of wild-type CCR5, whereas that of mutant C269A was 10 to 20% of that of wild-type CCR5, depending on the test isolate that was used. It is predicted that the extracellular domains of CCR5 are constrained by two disulfide bridges: one between C101 in ECL1 and C178 in ECL2 and the other between C20 in the Nt and C269 in ECL3 (16) . Our results indirectly support this cysteine-pairing pattern since C20A (22) and C269A mutants are phenotypically indistinguishable in that they support similar levels of viral entry; the same is true for the C101A and C178A mutants. None of the other CCR5 mutants exhibited significantly altered coreceptor function; mutants Y89A, W94A, N98A, S169A, F182A, W190A, F263A, F264A, and N267A were the most affected, yet they only lost 40 to 60% of wild-type coreceptor activity, depending on the test isolate (Fig. 2) . Our results indicate that the individual side chains of the amino acids that we have studied do not play a significant role in coreceptor function. They do not exclude, however, the possibility that the amino acid main chains have a role in CCR5 coreceptor function (19, 23, 30) .
It is difficult to compare our results with those from other reports on the role of individual residues in the ECLs of CCR5 in coreceptor function. Whereas we have studied the function of single alanine substitutions in the context of human CCR5, others have looked at single or multiple non-alanine mutations in the context of nonhuman or chimeric receptors (11, 18, 24) . For example, Kuhmann et al. (18) have found that P183L in the context of the human-murine HHHHloop2M chimera and Q93R in the context of African green monkey (AGM) CCR5 impair HIV-1 coreceptor function; Ross et al. (24) have shown that S180P as well as some double mutations in human-murine CCR5 chimeras yield inefficient coreceptors; Doranz et al. (11) have observed that D11A, D11A/K197A, D11A/D276A, and D11A/K197A/D276A mutations in human CCR5 impair cellcell fusion. We found that the individual substitution of any of these residues II for alanine other than D11, has no significant effect on human CCR5 coreceptor function. The effect of a given mutation on coreceptor function therefore clearly depends on the context in which it is placed as well as on the kind of substitution that is introduced. Q93R in the context of AGM CCR5 impairs HIV-1 coreceptor function, whereas Q93A in the context of human CCR5 has no significant effect on viral entry (13, 18) .
Previously, we found that substitutions of alanine for charged residues in the ECLs of CCR5 had no significant effect on coreceptor function (13) . Now we show that other than for the structurally important cysteines, this is also true for residues with polar and bulky nonpolar side chains in the ECLs of CCR5. Altogether, our observations indicate that a gp120-binding site is located exclusively in the Nt domain of CCR5 (13, 22) . However, the conformational integrity of the ECLs is important for coreceptor function, since changing cysteine residues to alanines greatly reduces CCR5-mediated viral entry. Also, certain mutations in the ECLs lower viral entry in a weak but reproducible manner. Perhaps multiple, simultaneous substitutions of these residues would create a nonfunctional receptor (and thereby mimic certain chimeras). One interpretation of our results is that either gp120 or the CCR5 Nt domain makes low-affinity contacts with residues in the ECLs. In the latter case, the Nt would be held by these interactions in a conformation that would allow it to interact with gp120.
To determine whether disruption of Nt-to-ECL (or Nt-toplasma membrane) geometry is important for viral entry, we inserted spacers of 7, 14, or 21 alternating G/S residues between P19 and C20. We assumed that this would impair the formation of any noncovalent bonds that may otherwise form between ECL residues (or the plasma membrane) and Nt residues by increasing the flexibility of the latter. When normalized for protein expression, these insertions do not impair binding of the 2D7 MAb to CCR5 (data not shown), further indicating that CCR5 molecules carrying the G/S spacers are conformationally intact. MAb 2D7 recognizes epitopes in ECL2 (12, 29) , and its binding to CCR5 is decreased by ϳ50% when either C20 or C269 is changed to alanine (12) . Increasing G/S spacer length proportionally decreases NLluc ϩ env Ϫ /JR-FL entry: CCR5 with a 7-residue spacer has 19% wild-type activity, a 14-residue spacer lowers activity to 6% of that of the wild-type protein, and CCR5 with a 21-residue spacer no longer supports viral entry (Fig. 3) . Entry of dual-tropic NLluc ϩ env Ϫ /DH123 was even more severely affected (Fig. 3) . Therefore, the greater the degree of flexibility of the Nt domain, the less efficient the mutant coreceptor. This further supports the notion that CCR5 extracellular domain interactions are important for its coreceptor function. Disruption of the tertiary structure might account for the reduced coreceptor function of certain chimeric receptors (1, 5, 18, 21, 26, 29) .
We have shown that a gp120-binding site, composed of negatively charged and tyrosine residues, is contained between D2 and E18 of the Nt domain of CCR5 (13, 22) . This region needs to be in a specific orientation with regard to the CCR5 ECLs or the plasma membrane for viral entry to occur efficiently. There may be a two-step gp120-binding mechanism: the envelope glycoprotein might first interact with the Nt and then induce a snugger fit by forming a number of weak interactions with residues in the other ECLs. Alternatively, weak interactions between residues in the Nt and ECL1 to -3 or the plasma membrane might maintain the Nt in a conformation that is recognizable by gp120. We are presently exploring these possibilities.
